InveniAI and Ono Announce Target Discovery Collaboration
InveniAI Announces Collaboration with Ono Pharmaceutical for Target Discovery
19. Februar 2024 02:00 ET | InveniAI LLC
Teams will work together by leveraging InveniAI's technology platform to identify, evaluate, and optimize novel targets across Ono’s diseases of interestOno will access InveniAI’s AI platform...
Logo-InveniAI.png
InveniAI's AlphaMeld Platform Debuts the Addition of ChatAlphaMeld™, A Powerful Tool Designed to Scale Target and Drug Discovery and Development
04. April 2023 08:43 ET | InveniAI LLC
Powered by GPT-4, ChatAlphaMeld enables user interaction across functional stakeholders to automate hypothesis generation and prioritization Integrated into the AlphaMeld workflow, ChatAlphaMeld is...
Logo-InveniAI.png
InveniAI and Kyowa Kirin Expand AI-Driven Partnership to a Multi-Year Strategic Collaboration for the Discovery of Novel Targets and Treatments Across Therapeutic Areas
16. Dezember 2021 08:10 ET | InveniAI LLC
Collaboration enables Kyowa Kirin's R&D team to access InveniAI's data-driven discovery platform in expanded therapeutic areasInveniAI's AlphaMeld® platform to provide unique Translational Edge...